EP4138823 - METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 27.01.2023 Database last updated on 22.08.2024 | |
Former | The international publication has been made Status updated on 29.10.2021 | ||
Former | unknown Status updated on 17.05.2021 | Most recent event Tooltip | 02.04.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states BerGenBio ASA P.O. Box 2324 Møllendal 5867 Bergen / NO | For all designated states The Board of Regents of the University of Texas System 210 West 7th Street Austin, Texas 78701 / US | [2023/09] | Inventor(s) | 01 /
LORENS, James BerGenBio ASA Jonas Lies Vei 91 5009 Bergen / NO | 02 /
MICKLEM, David BerGenBio ASA Jonas Lies Vei 91 5009 Bergen / NO | 03 /
LI, Huiyu 5940 Forest Park Rd, Apt 4094 Dallas, TX 75235 / US | 04 /
LIU, Zhida 7 Xinhua Road Xiaodian District Taiyuan City Shanxi Province, 030032 / CN | 05 /
MINNA, John 5323 Harry Hines Blvd. Dallas, TX 75390-9141 / US | 06 /
BREKKEN, Rolf 3822 Vancouver Cir. Dallas, TX 75229 / US | [2023/09] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2023/09] | Application number, filing date | 21724013.4 | 23.04.2021 | [2023/09] | WO2021GB50999 | Priority number, date | GB20200006072 | 24.04.2020 Original published format: GB 202006072 | US202063118764P | 27.11.2020 Original published format: US 202063118764 P | US202163144296P | 01.02.2021 Original published format: US 202163144296 P | US202163152654P | 23.02.2021 Original published format: US 202163152654 P | [2023/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021214492 | Date: | 28.10.2021 | Language: | EN | [2021/43] | Type: | A1 Application with search report | No.: | EP4138823 | Date: | 01.03.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.10.2021 takes the place of the publication of the European patent application. | [2023/09] | Search report(s) | International search report - published on: | EP | 28.10.2021 | Classification | IPC: | A61K31/4196, A61K45/06, A61P35/00, A61K39/00 | [2023/09] | CPC: |
A61K45/06 (EP,IL,KR,US);
A61K31/502 (EP,IL,KR);
C07K16/2863 (EP,IL,US);
A61K31/506 (KR);
A61K39/001102 (EP,IL,KR,US);
A61K39/39541 (EP,IL,KR);
A61P35/00 (EP,IL,KR,US);
C07K16/2818 (EP,IL);
C07K16/2866 (EP,IL);
C12Q1/6886 (KR);
G01N33/5748 (EP,IL);
G01N33/57496 (EP,IL,KR);
A61K2039/505 (EP,IL,KR,US);
A61K2300/00 (IL,KR);
C12Q2600/106 (KR);
| C-Set: |
A61K31/502, A61K2300/00 (EP);
A61K39/39541, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/09] | Title | German: | VERFAHREN ZUR AUSWAHL VON PATIENTEN ZUR BEHANDLUNG MIT EINER KOMBINATION AUS EINEM AXL-HEMMER UND EINEM IMMUNCHECKPOINT-MODULATOR | [2023/09] | English: | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | [2023/09] | French: | PROCÉDÉ DE SÉLECTION DE PATIENTS POUR UN TRAITEMENT AVEC UNE COMBINAISON D'UN INHIBITEUR AXL ET D'UN MODULATEUR DE POINT DE CONTRÔLE IMMUNITAIRE | [2023/09] | Entry into regional phase | 03.11.2022 | National basic fee paid | 03.11.2022 | Designation fee(s) paid | 03.11.2022 | Examination fee paid | Examination procedure | 03.11.2022 | Amendment by applicant (claims and/or description) | 03.11.2022 | Examination requested [2023/09] | 03.11.2022 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 03.11.2022 | Renewal fee patent year 03 | 31.03.2024 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XDYI]WO2016193680 (BERGENBIO AS [NO], et al); | [XYI]WO2018022438 (LILLY CO ELI [US]); | [XY]WO2018193102 (ADC THERAPEUTICS SA [CH], et al); | [XPY]WO2021032883 (BERGENBIO ASA [NO]); | by applicant | US4816567 | WO2007030680 | WO2007044515 | US2007213375 | WO2008045978 | US2008117789 | US2008153815 | WO2008080134 | WO2008083353 | WO2008083357 | WO2008083354 | WO2008083356 | WO2008083367 | US2008176847 | US2008182862 | US2008188454 | US2008188455 | US2008188474 | US2009111816 | WO2009054864 | WO2009063965 | WO2009062690 | WO2010083465 | WO2010130751 | EP2267454 | WO2011159980 | WO2012028332 | US2012121587 | WO2012175691 | WO2012175692 | WO2013064685 | WO2014068139 | WO2015193428 | WO2015193430 | WO2016097370 | WO2016166296 | WO2016193680 | WO2017220695 |